Last week, Steven Davidoff Solomon, the Deal Professor at the New York Times DealBook, earned a 'C' for his clumsy takedown of the Allergan-Valeant-Pershing Square situation. He did worse this week, and earns a 'D' for a poorly-reported, if not outright biased account of "gadfly" shareholders.

You can find other useful resources at the TAI website, including our research on "Effective Activism, on the Cheap", our new resource guide on activist investing data sources, our white paper with the basics on activist investing, and our new guides on exempt solicitation, consent solicitation, and special shareholder meetings. 

For further information, please contact:

Michael R. Levin
m.levin@theactivistinvestor.com
847.830.1479